A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy

V. A. Ferro, J. H. Morris, W H Stimson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.

LanguageEnglish
Pages13-25
Number of pages13
JournalDrug Design and Discovery
Volume13
Issue number1
Publication statusPublished - Aug 1995

Fingerprint

Neutron Capture Therapy
Boron
Boron Compounds
Streptavidin
Antibodies
Poisons
Biotin
Lysine
Glutamic Acid
Polymers
Monoclonal Antibodies
Neoplasms

Keywords

  • antibodies
  • antibody specificity
  • bacterial proteins
  • boron compounds
  • boron neutron capture therapy
  • small cell carcinoma
  • cell death
  • tumor cells
  • lung neoplasms
  • polyglutamic acid
  • polylysine
  • streptavidin

Cite this

@article{b02c7bdc23944fceb15ebeb31a6ba848,
title = "A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy",
abstract = "The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.",
keywords = "antibodies, antibody specificity, bacterial proteins, boron compounds, boron neutron capture therapy, small cell carcinoma, cell death, tumor cells, lung neoplasms, polyglutamic acid, polylysine, streptavidin",
author = "Ferro, {V. A.} and Morris, {J. H.} and Stimson, {W H}",
year = "1995",
month = "8",
language = "English",
volume = "13",
pages = "13--25",
journal = "Drug Design and Discovery",
issn = "1055-9612",
number = "1",

}

A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy. / Ferro, V. A.; Morris, J. H.; Stimson, W H.

In: Drug Design and Discovery, Vol. 13, No. 1, 08.1995, p. 13-25.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A novel method for boronating antibodies without loss of immunoreactivity, for use in neutron capture therapy

AU - Ferro, V. A.

AU - Morris, J. H.

AU - Stimson, W H

PY - 1995/8

Y1 - 1995/8

N2 - The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.

AB - The search for suitable boron containing compounds for 10B neutron capture therapy (BNCT) is based on the principle that boron atoms must be delivered specifically to tumour cells at a concentration high enough to be effective without being toxic to normal cells. Specificity may be achieved through monoclonal antibodies. However, it has been difficult to conjugate large numbers of boron atoms to the antibody molecules without inactivating them. We have devised a strategy to do this indirectly through the use of a boronated glutamate-lysine polymer in conjunction with biotin and streptavidin.

KW - antibodies

KW - antibody specificity

KW - bacterial proteins

KW - boron compounds

KW - boron neutron capture therapy

KW - small cell carcinoma

KW - cell death

KW - tumor cells

KW - lung neoplasms

KW - polyglutamic acid

KW - polylysine

KW - streptavidin

M3 - Article

VL - 13

SP - 13

EP - 25

JO - Drug Design and Discovery

T2 - Drug Design and Discovery

JF - Drug Design and Discovery

SN - 1055-9612

IS - 1

ER -